Genetically Modified Rabbits for Cardiovascular Research

Jianglin Fan1,2,3*, Yanli Wang1 and Y. Eugene Chen4

1 Department of Pathology, Xi’an Medical University, Xi’an, China, 2 Department of Molecular Pathology, Faculty of Medicine, Graduate School of Interdisciplinary Research, University of Yamanashi, Yamanashi, Japan, 3 School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, China, 4 Center for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, Ann Arbor, MI, United States

Rabbits are one of the most used experimental animals for investigating the mechanisms of human cardiovascular disease and lipid metabolism because they are phylogenetically closer to human than rodents (mice and rats). Cholesterol-fed wild-type rabbits were first used to study human atherosclerosis more than 100 years ago and are still playing an important role in cardiovascular research. Furthermore, transgenic rabbits generated by pronuclear microinjection provided another means to investigate many gene functions associated with human disease. Because of the lack of both rabbit embryonic stem cells and the genome information, for a long time, it has been a dream for scientists to obtain knockout rabbits generated by homologous recombination-based genomic manipulation as in mice. This obstacle has greatly hampered using genetically modified rabbits to disclose the molecular mechanisms of many human diseases. The advent of genome editing technologies has dramatically extended the applications of experimental animals including rabbits. In this review, we will update genetically modified rabbits, including transgenic, knock-out, and knock-in rabbits during the past decades regarding their use in cardiovascular research and point out the perspectives in future.

Keywords: atherosclerosis, CRISPR-Cas9, hypercholesterolemia, knock-out rabbits, transgenic rabbits

INTRODUCTION

Rabbits were first used for disclosing the pathogenesis of human atherosclerosis a century ago. In 1908, a Russian physician, Alexander I. Ignatowski (1875–1955) fed rabbits with a diet supplemented with animal proteins (milk, meat, and eggs) and found that these rabbits developed pronounced aortic atherosclerosis.

Later, a Russian experimental pathologist, Nikolai N. Anichkov (or Anitschkow) (1885–1964) further demonstrated that it was dietary cholesterol rather than proteins that play the critical role in the pathogenesis of atherosclerosis in rabbits and proposed a causal role of cholesterol in the development of atherosclerosis (Fan et al., 2015). Now, a consensus has been widely hold in this field that, in both humans and experimental animals, high levels of plasma cholesterol carried by apolipoprotein (apo)-B-containing particles such as low density lipoproteins (LDL) initiate the development of atherosclerosis (Steinberg, 2004). These pioneering studies derived from rabbit experiments not only provided the first evidence but also established a theory basis of the “lipid hypothesis” of atherosclerosis (Steinberg, 2004). Since then, cholesterol-fed rabbits along with Watanabe heritable hyperlipidemic (WHHL) rabbits, a mutant rabbit with genetic deficiency of LDL receptor
functions, have been extensively used to elucidate multiple facets of the pathophysiology of human atherosclerosis, leading to the discovery of the LDL receptor functions in familial hypercholesterolemia (Goldstein et al., 1983) and the development of the most-prescribed lipid-lowering drug, statin (Brown and Goldstein, 2004). On the other hand, transgenic rabbits with overexpression of various genes were generated from early 90’s and served as an alternative tool for investigating the gene functions in cardiovascular disease. Moreover, recent genome editing technology has provided enormous opportunities to create knock-out (KO) and knock-in (KI) rabbits. Important roles of rabbits in studying human atherosclerosis have been extensively reviewed in the previous reviews (Fan et al., 1999a, 2015, 2018; Fan and Watanabe, 2000, 2003). In this review, we will focus on genetically modified rabbits for their applications in cardiovascular research.

**“NATURALLY” GENETICALLY MODIFIED RABBITS**

Spontaneous mutations in rabbits can be found accidentally and they can be used in controlling the coat color for commercial purposes such as tyrosinase and the melanocortin 1 receptor (Aigner et al., 2000; Xiao et al., 2019). However, some spontaneous mutations in rabbits can cause a pronounced phenotype that can mimic human diseases, such as Watanabe heritable hyperlipidemic (WHHL) rabbits (Watanabe, 1980), St. Thomas hyperlipidemic rabbits (Laville et al., 1987; Seddon et al., 1987) and complement 6 deficient rabbits (Rother, 1986; Liu et al., 2007a). WHHL rabbits were originally established by Dr. Yoshio Watanabe (1927–2008) at Kobe University, Japan, through serial inbreeding (Watanabe, 1980). Homozygous WHHL rabbits exhibit spontaneous hypercholesterolemia characterized by high levels of LDLs and severe atherosclerosis and often serve as a human familial hypercholesterolemia model (Watanabe et al., 1985). Genetic analysis revealed that WHHL rabbits have defective LDL receptor functions due to a deletion of 12 nucleotides in exon 4 of the LDL receptor gene, which leads to a 4-amino acid deletion in the cysteine-rich ligand-binding domain of the LDL receptor protein (Yamamoto et al., 1986). LDL receptor mutations can be easily detected by PCR analysis (Sun et al., 2002a); however, high levels of plasma LDL-cholesterol are the major manifestation observed in homozygous WHHL rabbits. In addition to hyperlipidemia and aortic atherosclerosis, some WHHL rabbits (later designated as WHHL-MI) show coronary atherosclerosis and myocardial infarction (Shiomi et al., 2003; Shiomi and Fan, 2008). Using WHHL rabbits, Tomoike et al. further developed a subline of WHHL designated a hereditary hypertriglyceridemic rabbit after selected in-breeding. This model exhibited postprandial hypertriglyceridemia along with insulin resistance and visceral obesity although polygenetic loci for these pathophysiological changes have not been determined (Kawai et al., 2006). In addition to WHHL rabbits, the St. Thomas hospital hyperlipidemic rabbits were developed by La Ville et al. in London (Laville et al., 1987; Seddon et al., 1987). Different from WHHL rabbits which have high plasma LDL levels due to LDL receptor dysfunctions, the St. Thomas hospital hyperlipidemic rabbits showed high levels of very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL), and LDL, thus this rabbit model resembles human familial combined hyperlipidemia. Elevated plasma cholesterol levels in these rabbits were caused by overproduction of these apo-B-containing lipoproteins in the liver although the genetic mutations responsible for hyperlipidemia have not been examined in detail. There is a complement-6 (C6) deficient rabbit originally reported by Rother in 1986 (Rother, 1986). C6 deficiency in these rabbits arises from a single gene defect and is not known to be associated with other genetic abnormalities. In spite of this, C6 deficient rabbits are protective against cholesterol diet-induced atherosclerosis (Schmiedt et al., 1998).

**TRANSGENIC RABBITS**

Because spontaneous mutant rabbits with obvious phenotypes resembling human disease phenotypes are rare and accidently discovered by experimental animal staff, it is necessary to make genetically modified rabbits according to one’s own research purposes. The technology for producing transgenic (Tg) rabbits was almost concurrently reported by German (Brem et al., 1985) and US (Hammer et al., 1985) groups in 1985, but the actual use of Tg rabbit technology as an experimental tool in the field of cardiovascular diseases was not realized until 1994 when John Taylor's laboratory at the Gladstone Institute of Cardiovascular Disease in San Francisco created the first Tg rabbit expressing human hepatic lipase (Fan et al., 1994). Later on, they also produced Tg rabbits expressing human apoB-100 (Fan et al., 1995), apoE (Huang et al., 1997; Fan et al., 1998), and apoB mRNA editing protein (Yamanaka et al., 1995). Until now, more than 20 kinds of Tg rabbits expressing different genes that are involved in lipid metabolism and atherosclerosis have been reported and studies using these Tg rabbits have provided considerable insights into the molecular mechanisms of these gene functions in lipoprotein metabolism and atherosclerosis (Fan and Watanabe, 2003; Peng, 2012; Fan et al., 2015). The transgenes expressed in Tg rabbits for the study of lipoprotein metabolism and atherosclerosis can generally be classified into three categories: (1) those proteins that constitute lipoprotein structures such as apo(a) (Rouy et al., 1998; Fan et al., 1999b), apoAI (Duverger et al., 1996a), apoAII (Koike et al., 2009a; Wang et al., 2013), apoB-100 (Fan et al., 1995), apoCIII (Ding et al., 2011), and apoE (Huang et al., 1997; Fan et al., 1998); (2) those enzymes or transfer proteins that participate in the lipid metabolism such as hepatic lipase (Fan et al., 1994), lipoprotein lipase (Fan et al., 2001a), phospholipid transfer protein (Masson et al., 2011), apoB-100 mRNA editing enzyme catalytic polypeptide protein (Yamanaka et al., 1995), lecithin:cholesterol acyltransferase (Hoeg et al.,...
1996), endothelial lipase (Wang et al., 2017); and (3) those proteins that may exert some functions on the arterial wall cells which participate in the pathogenesis of atherosclerosis including matrix metalloproteinase-1,9,12 (Liang et al., 2006; Niimi et al., 2019; Chen et al., 2020), 15-lipoxygenase (Shen et al., 1996), C-reactive protein (Koike et al., 2009b), and vascular endothelial growth factor (Kitajima et al., 2005) (Table 1). In addition, Tg rabbits have also been used for the investigation of human heart diseases, including LQT syndrome (Brunner et al., 2008), hypertrophic cardiomyopathy (Marian et al., 1999) and tachycardia-induced cardiomyopathy (Suzuki et al., 2009). This is because, in comparison with mice and rats, the rabbit heart is similar to that of humans in both structure and function (Bers, 2002; Marian, 2006; Pogwizd and Bers, 2008). For example, like human heart in which β-myosin heavy chain (β-MyHC) accounts for 90% of total myofibrillar myosin, rabbit heart is composed of 80% β-MyHC which is different from the mouse heart predominated by 95% α-MyHC (Marian, 2005; Bosze et al., 2016). Tg rabbits can be generated by microinjecting a transgenic DNA construct into the pronuclei of fertilized embryos (Fan et al., 1999a; Kitajima et al., 2003). The transgenic constructs are typically composed of the transgene (either cDNA or genomic DNA) under the control of a tissue-specific promoter such as liver- and macrophage-specific promoter. In addition to the pronuclear microinjection method, other methods such as sperm vector (Wang et al., 2003; Li et al., 2006, 2010; Shen et al., 2006), ICSI-mediated transgenesis (Li et al., 2010; Zhang et al., 2016), somatic cell nuclear transfer (SCNT) (Li et al., 2009) or chimeric SCNT (Matsuda et al., 2002; Skrzyszowska et al., 2006), lentiviral vectors (Hiripi et al., 2010), transposon-mediated transgenesis (Katter et al., 2013; Ivics et al., 2014), and novel genome editing technology (Song et al., 2016; Yang et al., 2016; Li et al., 2019) have been reported to produce Tg rabbits. In spite of this, the pronuclear microinjection is still the most common method even though transgene integration rate is low.

**RABBIT EMBRYONIC STEM CELLS AND GENOME INFORMATION**

Because of the lack of both rabbit embryonic stem (ES) cells and the genome information, it has been considered impossible to create KO rabbits by homologous recombination-based genomic modification as to generate KO mice. Unavailability of KO rabbits also constitutes another obstacle that hampers researchers to study loss-of-functions of genes in rabbits. We strived to use somatic cell nuclear transfer technique to generate KO rabbits after Chesne et al. reported the first cloned rabbit about 17 years ago (Chesne et al., 2002). However, after enormous attempts, we got to the conclusion that the production of KO rabbits by somatic cell nuclear transfer is far remote from reality. As a research tool, nuclear transfer technique is unworkable owing to the extraordinarily low efficiency of gene transfer into somatic cells and the possibility in generating cloned rabbits (Song J. et al., 2020). Many groups reported that they could obtain rabbit ES-like cells, but none of these so-called ES-like cells have been proved to be able to generate chimera rabbits (Fan et al., 2015). Rabbit genome has long been an empty area mainly because of budget insufficiency and narrow research communities. In 2014, Carneiro et al. successfully reported a high-quality reference genome using the European rabbit with references to domestication and speciation (Carneiro et al., 2014a,b). Almost at the same period, we along with researchers from the US, Japan and China organized an International Rabbit Genome Sequencing Project Consortium aiming at implementing more extensive whole-genome sequencing of three kinds of common laboratory rabbits: Japanese white rabbits, New Zealand white rabbits and WHHL rabbits. In addition, we performed deep transcriptome sequencing of the aortas, livers, hearts, and kidneys of cholesterol-fed and WHHL rabbits (Wang et al., 2016). After a 2-year collaborative work, we were able to completed whole-genome sequencing of 10 male rabbits for each line with coverage of 13x for each individual after alignment to the reference genome. With the successful completion of rabbit genome sequencing (Carneiro et al., 2014a,b; Wang et al., 2016), researchers now can easily not only design PCR primers to study gene expression in rabbits but also to generate KO rabbits using genome editing techniques as described below. Rabbit genome information is now available from the NCBI database and a comprehensive rabbit transcriptome information established by the Chinese Academy of Sciences in Shanghai (Zhou et al., 2018) is also available at http://www.picb.ac.cn/RabGTD/.

**KNOCK-OUT AND KNOCK-IN RABBITS BY GENOME EDITING TECHNIQUES**

In the past decade, the emergence of three powerful genome editing technologies has dramatically enhanced the application of genetically modified rabbits (Song J. et al., 2020). The first one is the zinc finger nuclease (ZFN)-mediated genome editing method by which KO rats were successfully created in 2009 (Geurts et al., 2009). Two years later after the birth of KO rats, Flisikowska et al. generated the first immunoglobulin KO rabbits in an attempt to produce humanized antibodies (Flisikowska et al., 2011). Almost at the same time, we successfully created apoCIII KO rabbits with ZFN-mediated genome editing technology (Yang et al., 2013). ZFNs are engineered DNA-cleaving enzymes made by fusing a tailor-made DNA-binding domain to the DNA cleavage domain of FokI, a type II restriction enzyme. ZFNs generate site-specific double-strand breaks in the DNA at researcher-assigned sites, thus resulting in targeted modification of the genome. However, while ZFNs were not extensively applied in this field, the second generation of the genome editing tool, transcription activator-like effector nucleases (TALEN) were shown up to make the first KO rats in 2011 (Tesson et al., 2011). TALENs are considered much simpler to design and assemble than ZFNs. The DNA binding domain in TALENs was derived from *Xanthomonas spp. Bacteria* (Christian et al., 2010; Miller et al., 2011). While TALENs utilize the same FokI endonuclease domain as ZFNs, its DNA binding domain contains a repeated highly conserved 33–34 amino acid sequence with divergent 12th and 13th amino acids which called Repeat Variable
TABLE 1 | Transgenic rabbits for the study of human lipoproteins and atherosclerosis.

| Genes                        | Expression cells | Major phenotypes | References                                                                 |
|------------------------------|------------------|------------------|-----------------------------------------------------------------------------|
| Apolipoproteins (apo)        |                  |                  |                                                                             |
| Apo(a)                       | Liver            | Atherogenic      | Rouy et al., 1998; Fan et al., 2001b; Ichikawa et al., 2002; Sun et al., 2002b; Kitajima et al., 2007 |
| Apo(a) and apoB               | Liver            | Not determined   | Rouy et al., 1998                                                         |
| ApoA-I                       | Liver            | Athero-protective| Duverger et al., 1996a,b                                                   |
| ApoA-II                      | Liver            | Athero-protective| Koike et al., 2009a; Wang et al., 2013                                    |
| ApoA-I/C-III/A-IV             | Liver and intestine | No effect on atherosclerosis | Recalde et al., 2004                                                      |
| ApoB-100                     | Liver            | LDL↑, HDL↓        | Fan et al., 1995                                                          |
| ApoCIII                      | Liver            | VLDL↑            | Ding et al., 2011                                                          |
| ApoE2                        | Liver            | Atherogenic      | Huang et al., 1997                                                       |
| ApoE3                        | Liver            | Atherogenic      | Fan et al., 1998; Huang et al., 1999                                      |
| Enzymes or transfer proteins |                  |                  |                                                                             |
| APOPEC1                      | Liver            | LDL↓, liver carcinoma | Yamanaka et al., 1995                                                   |
| APOPEC1 Knockdown by RNAi     | Macrophage       | Lean             | Jolivet et al., 2014                                                      |
| CETP                         | Liver            | HDL↓             | Gao et al., 2017                                                          |
| Endothelial lipase           | Liver            | Athero-protective| Wang et al., 2017; Yan et al., 2020b                                     |
| Hepatic lipase               | Liver            | Athero-protective| Fan et al., 1994                                                          |
| LCAT                         | Liver            | Athero-protective| Hoeg et al., 1996                                                         |
| Lipoprotein lipase           | Universal        | Athero-protective| Fan et al., 2001a                                                         |
| PLTP                         | Universal        | Atherogenic      | Masson et al., 2011                                                      |
| Vascular cell factors        |                  |                  |                                                                             |
| C-reactive protein           | Liver            | Thrombogenic     | Matsuda et al., 2011                                                      |
| Lipoprotein lipase           | Macrophage       | Atherogenic      | Ichikawa et al., 2005                                                    |
| 15-lypoxygenase              | Macrophage       | Athero-protective| Shen et al., 1996                                                         |
| MMP-1                        | Macrophage       | Aortic aneurysm↑ | Nimi et al., 2019                                                        |
| MMP-9                        | Macrophage       | Vascular calcification | Chen et al., 2020                                                      |
| MMP-12                       | Macrophage       | Atherogenic      | Liang et al., 2006; Yamada et al., 2008                                   |
| Urotensin II                 | Macrophage       | Atherogenic      | Zhao et al., 2015                                                        |
| VEGF                         | Liver            | Hemangiomas and impaired glomerular functions | Kitajima et al., 2005; Liu et al., 2007b                                   |

APOPEC1, apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1; CETP, cholesteryl ester transfer protein; LCAT, lecithin:cholesterol acyltransferase; PLTP, phospholipid transfer protein; MMP, matrix metalloproteinase; VEGF, vascular endothelial cell growth factor. ↑, increase; ↓, decrease.

Diresidue (RVD) for recognizing one specific nucleotide, for example, NN for guanine, NI for adenine, HD for cytosine, and NG for thymine. This direct relationship between amino acid sequence and DNA recognition has made engineering sequence specific binding domains much easier than ZFNs (Boch et al., 2009; Moscou and Bogdanove, 2009). Using TALEN technology, Lai's laboratory at GIBH, immediately generated two kinds of KO rabbits: an immunodeficient KO rabbit with deficiency of Rag1 and Rag2 genes (Song et al., 2013) and fumarylacetocetate hydroxase deficient rabbits (Li et al., 2017), which mimics human genetic disease tyrosinemia type I, an autosomal recessive disorder caused by mutations in the both copies of the gene encoding the enzyme. Although TALENs are considered superior to ZFNs in terms of fewer off-target effects, easy design and production, it was soon replaced by the CRISPR-Cas9 based genome editing technology, which is even more rapid and modular than the TALEN platform. Cas9 is an endonuclease playing a protective role against foreign nucleic acids in the adaptive immune system in bacteria. The feature of bacterial CRISPR immune system is that genetic materials taken up from previous invasive elements are expressed in crRNA, which could direct the Cas9 endonuclease to cut foreign DNA elements containing the same sequences (Jinek et al., 2012). Therefore, the CRISPR/Cas9 system has been remodeled from bacterial immune system to the genome editing tool, using a designed RNA to guide Cas9 nuclease to the specific DNA sequence (Hsu et al., 2014). Binding of Cas9 nuclease on a specific protospacer adjacent motif (PAM) sequence on the genome (NGG for spCas9) will unwind the adjacent sequence, allowing the RNA:DNA pairing, which activates the nuclease domains in Cas9 to cut DNA and make double-strand breaks. While ZFNs and TALENs rely on protein-DNA recognition, which is less predictable for design and more labor and time consuming for assembly, the CRISPR/Cas9 system relies on the RNA–DNA recognition, which is much simpler and more predictable.

Because CRISPR-Cas9 technique is so efficient and powerful, it was quickly adopted to generate KO rabbits. In this respect, Chen's laboratory at the University of Michigan first established a number of KO rabbits aiming at studying human cardiovascular disease (Yang et al., 2014) and then KO rabbit boom started. Lai's
laboratory at GIBH and Li’s laboratory at Jilin University made more than 30 KO rabbits using CRISPR-Cas9 along with base-editing (Liu et al., 2018) and CRISPR/Cpf1 (Wu et al., 2018). Most KO rabbits were created in attempt to recapitulate human genetic or congenital disorders or immunodeficient rabbits (Song J. et al., 2017, 2018) as shown in Table 2. In addition, this technique has been tried to target the tyrosinase gene to modify rabbit coat colors (Honda et al., 2015; Song Y. N. et al., 2016, 2017, 2018). The standard protocol for generation of KO rabbits using CRISPR-Cas9 has been recently published (Yang et al., 2019). The techniques have been further refined (Liu et al., 2018, 2020) so we can predict that in the next few years, more and more KO or KI rabbits will be made using this technology. Here we will briefly review some valuable KO rabbits created recently to discuss their usefulness in disclosing the molecular mechanisms of atherosclerosis.

APOCIII KO RABBITS

ApoCIII is a major component of plasma chylomicrons and VLDLs, and is a minor component of high density lipoproteins (HDLs) and was first reported by Brown et al. 50 years ago (Brown et al., 1969). It is generally believed that physiological functions of apoCIII is to mediate the triglyceride(TG)-rich lipoprotein metabolism thereby maintaining the plasma TG homeostasis and high plasma levels of apoCIII are positively associated with plasma TG and increases the risk of ischemic heart disease (Huff and Hegele, 2013; Norata et al., 2015; Ramms and Gordts, 2018). However, for a long time, it is not clear whether apoCIII was directly involved in the pathogenesis of atherosclerosis because mouse models failed to provide a clear answer (Yan et al., 2020a). Yang et al. first generated apoCIII KO rabbits using ZNF (Yang et al., 2013) and after several years efforts to breed enough numbers of homozygous apoCIII KO rabbits, we were able to examine the hypothesis whether apoCIII may participate in atherosclerosis. Recently, we have shown that genetic deletion of the apoCIII gene in KO rabbits significantly accelerates catabolism of TG-rich lipoproteins in the liver and apoCIII deficiency leads to the resistance of KO rabbits to a cholesterol diet-induced hyperlipidemia and inhibits atherosclerosis (Yan et al., 2020a). These results indicate that therapeutic inhibition of apoCIII expression may become a novel strategy for the treatment of hyperlipidemia and atherosclerosis.

APOE KO RABBITS

ApoE is a ligand for both LDL receptor and LRP and plays an important role in the catabolism of remnant lipoproteins in the liver and genetic deficiency of apoE is a cause of human type III hyperlipoproteinemia (Mahley, 1988; Mahley et al., 1999). Deletion of apoE in mice even on a normal chow diet exhibited hyperlipidemia along with spontaneous aortic atherosclerosis (Plump et al., 1992; Zhang et al., 1992). ApoE KO rabbits were produced at University of Michigan using CRISPR-Cas9 (Yang et al., 2014) and Sage Company using ZFN (Ji et al., 2015), respectively. Even though different techniques were adopted, apoE KO rabbits generated by these two methods exhibit the same phenotypes (Niimi et al., 2016). Homozygous apoE KO rabbits on a normal diet only showed mild hyperlipidemia and their plasma total cholesterol levels reached ∼200 mg/dL, similar to human type III hyperlipoproteinemia patients, whose cholesterol levels are elevated to 300~350 mg/dL (Mahley et al., 1999). Because plasma levels of cholesterol in apoE KO rabbits on a normal diet are not high to be atherogenic, there are not spontaneous atherosclerosis, which is different from apoE KO mice. However, when apoE KO rabbits were fed a cholesterol diet, they developed more prominent hypercholesterolemia than WT rabbits, which is basically caused by the remarkable accumulation of intestinally-derived remnant lipoproteins, β-VLDLs (Niimi et al., 2016). Recently, we found that apoE KO rabbits are highly susceptible to a cholesterol diet-induced atherosclerosis. Therefore, apoE KO rabbits will serve as a new model for human hyperlipidemia.

LDL RECEPTOR KO RABBITS

In humans, genetic deficiency of LDL receptor functions causes severe hypercholesterolemia and atherosclerosis at early ages, called familial hypercholesterolemia (FH). FH is an autosomal dominant genetic disorder characterized by elevated plasma LDL levels due to LDL receptor dysfunctions (Soutar and Naoumova, 2007). Two laboratories have successfully generated LDL receptor KO rabbits using CRISPR-Cas9 (Yang et al., 2014; Lu et al., 2018). Similar to human FH, homozygous LDL receptor KO rabbits develop spontaneous hypercholesterolemia and atherosclerosis (Lu et al., 2018). Therefore, like WHHL rabbits, LDL receptor KO rabbits can be used for the study of human FH.

CHOLESTERYL ESTER TRANSFER PROTEIN KO RABBITS

Cholesteryl ester transfer protein (CETP) is a glycoprotein that transfers plasma lipids between HDLs and apoB-containing particles therefore plays an important role in lipoprotein metabolism. However, it is not known whether inhibition of CETP activity can prevent cardiovascular disease because four CETP inhibitors (torcetrapib, dalcetrapib, evacetrapib, and anacetrapib) failed to prove their efficacy in terms of reduction of cardiovascular risk by clinical trials (https://en.wikipedia.org/wiki/CETP_inhibitor). Since CETP is genetically absent in rodents (mice and rats) and pigs, rabbits are considered the best model for investigation of CETP functions because rabbits have high levels of CETP in the plasma as humans. Taking this advantage, Zhang et al. created CETP KO rabbits and found that CETP KO rabbits showed higher plasma levels of HDL-cholesterol (Zhang et al., 2017). When fed a cholesterol-rich diet, CETP KO rabbits still exhibited higher HDL-cholesterol levels accompanied by lower total cholesterol levels than wild-type (WT) rabbits (Zhang et al., 2017). CETP KO rabbits had significant less atherosclerosis in both aorta and coronary arteries than WT rabbits (Zhang et al., 2017). These results indicate
that genetic ablation of CETP gene inhibits the development of atherosclerosis in cholesterol-fed rabbits.

**APOAII KI RABBITS**

ApoAII is the second major apolipoproteins in HDLs. However, its physiological functions are largely unknown compared with apoAI. Interestingly, WT rabbits are genetically deficient in apoAII so their HDLs only contain apoAI. This unique feature makes WT rabbits as a “natural” apoAII KO model. We first made Tg rabbits expressing human apoAII gene and found that hepatic expression of human apoAII inhibits cholesterol diet-induced atherosclerosis (Wang et al., 2013). To examine the apoAII specific functions in the absence of apoAI, we further replaced the rabbit endogenous apoAI with human apoAII gene through knock-in (KI) using TALEN technology (Koike et al., 2021). In this way, apoAII KI rabbits expressed exclusively human apoAII without apoAI in HDL particles, which enables us to compare the net functions of apoAI-only-HDLs in WT rabbits with apoAII-only-HDL in KI rabbits in terms of HDL metabolism and atherosclerosis. In the latest study, we found that apoAII KI rabbits showed consistently lower TG and higher HDL-cholesterol levels and developed significantly less aortic atherosclerosis on a cholesterol diet (Koike et al., 2021).

**CONSIDERATIONS AND FUTURE PERSPECTIVES**

Although genetically modified rabbits are an important experimental model in cardiovascular research, they should not be simply used as a substitute of mice and rats, as discussed above. Because rabbits are more expensive, require larger space, and need more time to breed compared with mice, the generation of genetically modified rabbits should be carefully planned to solve those specific problems that cannot be well-examined in other experimental animal models, such as the development of lipid-lowering drugs (Niimi et al., 2020). However, off-target effects in these animals remain a concern as the genome editing is extremely productive and efficient. So far, almost all studies claimed that off-targets in genetically modified rabbits through genome editing are either none or negligible as comprehensively discussed in the recent review (Song J. et al., 2020); nevertheless, there is a need to performed careful genotyping, including sequencing, and expression validation of genetically modified rabbit models. It can be expected that more and more genetically modified rabbits will be made and used in a variety of medical sciences which will certainly expand our knowledge to explore new mechanisms of human diseases. Genome editing technique may eventually replace the pronuclear microinjection for the generation of Tg rabbits. However, complicated gene manipulation in rabbits, such as conditional KO in an organ- or cell-specific and time-controlled manner using the Cre/LoxP system is still lacking, thus it will be absolutely necessary to build such a platform in future. Finally, the preservation of valuable strains of genetically modified rabbits is an urgent task with increased number of rabbit models produced. In this aspect, various procedures for cryopreservation of rabbit sperm (Vicente and Viudes-de-Castro, 1996; Dalimata and Graham, 1997; Nishijima et al., 2015) and embryos (al-Hasani et al., 1992; Kasai et al., 1992; Marco-Jimenez et al., 2016) have been reported but have not been standardized. In the future, it may be necessary to establish an international rabbit bio-resource center or sperm and embryo bank to stock and share valuable rabbit models worldwide.

**AUTHOR CONTRIBUTIONS**

JF, YW, and YC wrote the manuscript. All authors contributed to the article and approved the submitted version.
ACKNOWLEDGMENTS

We would like to thank the following people for their contribution to this project. Jun Song, Jie Xu, Dongshan Yang, and Jifeng Zhang at the University of Michigan, Yajie Chen, Tomonari Koike, and Manabu Niimi at University of Yamanashi, and Shuji Kitajima and Fumikazu Matsuhashi at Saga University.
Flisikowska, T., Thorey, I. S., Offner, S., Ros, F., Lifke, V., Zeiter, B., et al. (2011). Efficient immunoglobulin gene disruption and targeted replacement in rabbit using zinc finger nucleases. PLoS ONE. 6:e21045. doi: 10.1371/journal.pone.0021045

Gao, S., Wang, X., Cheng, D., Li, J., Li, L., Ran, L., et al. (2017). Overexpression of cholesterol ester transfer protein increases macrophage-derived foam cell accumulation in atherosclerotic lesions of transgenic rabbits. Mediators Inflamm. 2017:3824276. doi: 10.1155/2017/3824276

Geurts, A. M., Cost, G. J., Freyvert, Y., Zeiter, B., Miller, J. C., Choi, V. M., et al. (2009). Knockout rats via embryo microinjection of zinc-finger nucleases. Science 325:433. doi: 10.1126/science.1172447

Goldstein, J. L., Kita, T., and Brown, M. S. (1983). Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholesterolemia. N. Engl. J. Med. 309, 288–296. doi: 10.1056/NEJM19830843090057

Hammer, R. E., Purse, V. G., Rextroad, C. E. J., Wall, R. J., Bolt, D. J., Ebert, K. M., et al. (1985). Production of transgenic rabbits, sheep and pigs by microinjection. Nature 315, 680–683. doi: 10.1038/315680a0

Hiripi, L., Negre, D., Cosset, F. L., Kvell, K., Czompoly, T., Baranyi, M., et al. (2010). Transgenic rabbit production with simian immunodeficiency virus-derived lentiviral vector. Transgenic Res. 19, 799–808. doi: 10.1007/s11248-009-9356-y

Hoeg, J. M., Santamarina-fojo, S., Berard, A. M., Cornhill, J. F., Herderick, E. E., Feldman, S. H., et al. (1996). Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc. Natl. Acad. Sci. U.S.A. 93, 11448–11453. doi: 10.1073/pnas.93.21.11448

Honda, A., Hirose M., Sankai, T., Yasmin, L., Yuzawa, K., Honsho, K., et al. (2015). Single-generation rabbits carrying a targeted allele of the tyrosinase gene using CRISPR/Cas9. Exp. Animals 64, 31–37. doi: 10.15388/expanim.14-0034

Hsu, P. D., Lander, E. S., and Zhang, F. (2014). Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262–1278. doi: 10.1016/j.cell.2014.05.010

Huang, Y., Ji, Z. S., Brecht, W. J., Rall, S. C. Jr., Taylor, J. M., and Mahley, R. W. (2014). Lipid(a) enhances coronary atherosclerosis in transgenic Watanabe heritable hyperlipidemic rabbits. Atherosclerosis 219, 266–278. doi: 10.1016/j.atherosclerosis.2014.08.056

Kasai, M., Hamaguchi, Y., Zhu, S. E., Miyake, T., Sakurai, T., and Machida, T. (1992). High survival of rabbit morulae after vitrification in an ethylene glycol-based solution. Bio. Reprod. 46, 1042–1046. doi: 10.1095/biolreprod46.6.1042

Katter, K., Geurts, A. M., Hoffmann, O., Mates, L., Landa, V., Hiripi, L., et al. (2013). Transposon-mediated transgenesis, transgenic rescue, and tissue-specific gene expression in rodents and rabbits. FASEB J. 27, 930–941. doi: 10.1096/fj.12-205526

Kawai, T., Ito, T., Ohwada, K., Mera, Y., Matsushima, M., and Toinoie, H. (2006). Hereditary postprandial hypertriglyceridemic rabbit exhibits insulin resistance and central obesity - a novel model of metabolic syndrome. Arterioscler. Thrombo. Vasc. Biol. 26, 2752–2757. doi: 10.1161/ATVHA.100.3052488.12493.40

Kasai, S., Jin, Y., Koike, T., Yu, Y., Liu, E., Shiomi, M., et al. (2007). Lp(a) enhances coronary atherosclerosis in transgenic Watanabe heritable hyperlipidemic rabbits. Atherosclerosis 193, 269–276. doi: 10.1016/j.atherosclerosis.2006.08.056

Kasai, S., Liu, E., Morimoto, M., Koike, T., Yu, Y., Watanabe, T., et al. (2005). Transgenic rabbits with increased VEGF expression develop hemangomas in the liver: a new model for Kasabach-Merritt syndrome. Lab. Invest. 85, 1517–1527. doi: 10.1038/labinvest.3700346

Koike, T., Koike, Y., Yang, D., Guo, Y., Song, J., Xu, J., et al. (2021). Human apolipoprotein A-II reduces atherosclerosis in knock-in rabbits. Atherosclerosis 316, 32–40. doi: 10.1016/j.atherosclerosis.2020.11.028

Koike, T., Kitajima, S., Yu, Y., Li, Nishijima, K., Liu, E., et al. (2009a). Expression of human apoAII in transgenic rabbits leads to dyslipidemia: a new model for combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 29, 2047–2053. doi: 10.1161/ATVBAHA.109.190264

Koike, T., Kitajima, S., Yu, Y., Nishijima, K., Zhang, J., Ozaki, Y., et al. (2009b). Human C-reactive protein does not promote atherosclerosis in transgenic rabbits. Circulation. 120, 2088–2094. doi: 10.1161/CIRCULATIONAHA.109.872796

Laville, A., Turner P. R., Pittillo, R. M., Martini, S., Marenah, C. B., Rowles, P. M., et al. (1987). Hereditary Hyperlipidemia in the rabbit due to overproduction of Lipoproteins 1. biochemical-studies. Arteriosclerosis 7, 105–112. doi: 10.1161/01.ATV.7.2.105

Li, H., Li, Z., Xiao, N., Xu, S., Zhao, S., Zhang, Y., et al. (2019). Site-specific integration of rotavirus VP6 gene in rabbit beta-casein locus by CRISPR/Cas9 system. In Vitro Cell. Dev. Biol. Anim. 55, 586–597. doi: 10.1007/s11626-019-00382-z

Li, L., Shen, W., Min, L., Dong, H., Sun, Y., and Pan, Q. (2006). Human lactoferrin transgenic rabbits produced efficiently using dimethylsulfoxide-sperm-mediated gene transfer. Reproduc. Fertil. Dev. 18, 689–695. doi: 10.1046/j.1476-6309.2005.00601

Li, L., Zhang, Q., Yang, H., Zou, Q., Lai, C., Jiang, F., et al. (2017). Fumarylacetoacetate hydrolase knock-out rabbit model for hereditary tyrosinemia Type 1. J. Biol. Chem. 292, 4755–4763. doi: 10.1074/jbc.M116.764787

Li, Q., Hou, J., Wang, S., Chen, Y., and An, X. R. (2010). Production of transgenic rabbit embryos by intracytoplasmic sperm injection. Zygote 18, 301–307. doi:10.1016/j.sjp.2010.07.025

Li, S., Guo, Y., Shi, J., Yin, C., Xing, F., Xu, L., et al. (2009). Transgene expression of enhanced green fluorescent protein in cloned rabbits generated from in vitro-transfected adult fibroblasts. Transgenic Res. 18, 227–235. doi:10.1007/s11248-008-9227-y

Liang, J., Liu, E., Yu, Y., Kitajima, S., Koike, T., Jin, Y., et al. (2006). Macrograph metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits. Circulation 113, 1993–2001. doi: 10.1161/CIRCULATIONAHA.105.396031

Liu, E., Kitajima, S., Wiese, E., Reifenberg, K., Morimoto, M., Watanabe, T., et al. (2007a). Re-establishment of complement C6-deficient rabbit colony by cryopreserved sperm transported from abroad. Exp. Anim. 56, 167–171. doi: 10.1538/expanim.56.167

Liu, E., Morimoto, M., Kitajima, S., Koike, T., Yu, Y., Shiiki, H., et al. (2007b). Increased expression of vascular endothelial growth factor in kidney leads
to progressive impairment of glomerular functions. J. Am. Soc. Nephrol. 18, 2094–2104. doi: 10.1681/ASN.2006010075

Liu, T. J., Wang, J., Xie, X. D., Wang, K., Sui, T. T., Liu, D., et al. (2019). DMP1 Ablation in the rabbit results in mineralization defects and abnormalities in haversian Canal/Osteon microarchitecture. J. Bone Mineral Res. 34, 1115–1128. doi: 10.1002/jbmr.3683

Liu, Z. Q., Chen, M., Chen, S. Y., Deng, J. C., Song, Y. N., Lai, L. X., et al. (2018). Highly efficient RNA-guided base editing in rabbit. Nat. Commun. 9:2717. doi: 10.1038/s41467-018-05232-2

Liu, Z. Q., Shan, H. H., Chen, S. Y., Chen, M., Song, Y. N., Lai, L. X., et al. (2020). Highly efficient base editing with expanded targeting scope using ScSPCas9-N9 in rabbits. FASEB J. 34, 588–596. doi: 10.1096/fj.20191587R

Lu, R., Yuan, T., Wang, Y., Zhang, T., Yuan, Y., Wu, D., et al. (2018). Spontaneous severe hypercholesterolemia and atherosclerosis lesions in rabbits with deficiency of low-density lipoprotein receptor (LDLR) on exon 7. EBioMedicine 36, 29–38. doi: 10.1016/j.ebiom.2018.09.020

Lu, Y., Liang, M. M., Zhang, Q. J., Liu, Z. Q., Song, Y. N., Lai, L. X., et al. (2019). Mutations of GADD45G in rabbits cause cleft lip and palate syndrome (CL/P). Dis. Model. Mech. 12, 1619–1630. doi: 10.1242/dmm.038323

Ma, Y., Zhang, P., Lu, G., Zhao, J., Zheng, D., Ma, W., et al. (2017). Novel DMSO-sperm mediated exogenous DNA transfer method. Biotechnol. Rep. 19, 82–90. doi: 10.1016/j.btre.2017.07.013

Mahley, R. W. (1988). Apolipoprotein E:cholesterol transport paradoxes. J. Lipid Res. 29, 173–179. doi: 10.1194/jlr.R1000032198

Marcio-Jimenez, F., Jimenez-Trigos, E., Almela-Miralles, V., and Vincente, J. S. (2016). Development of cheaper embryo vitrification device using the minimum volume method. PLoS ONE 11:e0148661. doi: 10.1371/journal.pone.0148661

Matsuda, S., Yamashita, A., Nishijima, K., Kitajima, S., Koshimoto, C., Morimoto, M., Watanabe, T., Fan, J., et al. (2015). Motility and fertility of rabbit sperm cryopreserved using soybean lecithin as an alternative to egg yolk. Theriogenology 84, 1172–1175. doi: 10.1016/j.theriogenology.2015.06.018

Niimi, M., Nishijima, K., Kitajima, K., Matsuhisa, F., Koike, Y., Koike, K., et al. (2019). Macrophage-derived matrix metalloproteinase-1 accelerates aortic aneurysm formation in transgenic rabbits. J. Biomed. Res. 33, 271–279. doi: 10.7555/JBR.33.20180097

Niimi, M., Yang, D., Kitajima, S., Ning, B., Wang, C., Li, S., et al. (2016). ApoE knockout rabbits: a novel model for the study of human hyperlipidemia. Atherosclerosis 245, 187–193. doi: 10.1016/j.atherosclerosis.2015.12.002

Nishijima, K., Kitajima, S., Koshimoto, C., Morimoto, M., Watanabe, T., Fan, J., et al. (2015). Motility and fertility of rabbit sperm cryopreserved using soybean lecithin as an alternative to egg yolk. Theriogenology 84, 1172–1175. doi: 10.1016/j.theriogenology.2015.06.018

Norata, G. D., Tsimikas, S., Pirillo, A., and Catapano, A. L. (2015). Apolipoprotein C-III: from pathophysiology to pharmacology. Trends Pharmacol. Sci. 36, 675–687. doi: 10.1016/j.tips.2015.07.001

Peng, X. (2012). Transgenic rabbit models for studying human cardiovascular diseases. Comp. Med. 62, 472–9.

Plump, A. S., Smith, J. D., Hayek, T., Aalto-Setala, K., Walsh, A., Verstuyft, J. G., et al. (1992). Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71, 343–353. doi: 10.1016/0092-8674(92)90362-G

Pogwizd, S. M., and Bers, D. M. (2008). Rabbit models of heart disease. Drug Discov. Today Dis. Models 5, 185–193. doi: 10.1016/j.ddmod.2009.05.015

Ramms, B., and Gordts, P. (2018). Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism. Curr. Opin. Lipidol. 29, 171–179. doi: 10.1097/MOL.0000000000000502

Recalde, D., Baroukh, N., Viglietta, C., Prince, S., Verona, J., Vergnes, L., et al. (2004). Marie houdebine, human apoA-I/C-III/A-IV gene cluster transgenic rabbits: effects of a high-cholesterol diet. FEBS Lett. 572, 294–298. doi: 10.1016/j.febslet.2004.07.041

Rother, K. (1986). Rabbits deficient in C6. J. Lab. Pharmacol. 34, 1–4. doi: 10.1126/science.3283935

Rouy, D., Duverger, N., Lin, S. D., Emmanucl, F., Houdebine, L. M., Denefle, P., et al. (1998). Apolipoprotein(a) yeast artificial chromosome transgenic rabbits. Lipoprotein(a) assembly with human and rabbit apolipoprotein B J. Biol. Chem. 273, 1247–1251. doi: 10.1074/jbc.273.1.1247

Schmiedt, W., Kinscherf, R., Deigner, H. P., Kameclic, H., Nauen, O., Kilo, J., et al. (1998). Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler. Thromb. Vasc. Biol. 18, 1790–1795. doi: 10.1161/01.ATV.18.11.1790

Skrzyszowska, M., Smorag, Z., Slomski, R., Katska-Ksiazkiewicz, L., Kalak, R., et al. (2006). Generation of transgenic rabbits by the novel simple production of transgenic mice and rabbits using the new DMSO-sperm mediated exogenous DNA transfer method. Mol. Reprod. Dev. 73, 589–594. doi: 10.1002/mrd.20401

Shiomi, M., and Fan, J. (2008). Unstable coronary plaques and cardiac events in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits: questions and quandaries. Curr. Opin. Lipidol. 19, 631–636. doi: 10.1097/MOL.0b013e3283189c18

Shiomi, M., Ito, T., Yamada, K., Kawashima, S., and Fan, J. (2003). Development of an animal model for spontaneous myocardial infarction (WHHLMI rabbits). Arterioscler. Thromb. Vasc. Biol. 23, 1239–1244. doi: 10.1161/01.ATV.0000075947.28567.50

Skrzyszowska, M., Smorag, Z., Slomski, R., Katska-Ksiazkiewicz, L., Kalak, R., Michalak, E., et al. (2006). Generation of transgenic rabbits by the novel technique of chimeric somatic cell cloning. Biol. Reprod. 74, 1114–1120. doi: 10.1095/biolreprod.104.039370

Song, J., Wang, G. S., Hoenerhoff, M. J., Ruan, J. X., Yang, D. S., Zhang, J. F., et al. (2018). Bacterial and pneumocystis infections in the lungs of gene-knockout rabbits with severe combined immunodeficiency. Front. Immunol. 9:1429. doi: 10.3389/fimmu.2018.00429

Song, J., Wang, Y., Xu, J., Zhu, T., Chen, Y. E., and Zhang, J. (2016). R5-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency. Nat. Commun. 7:10548. doi: 10.1038/ncomms10548
Zhang, S. H., Reddick, R. L., Piedrahita, J. A., and Maeda, N. (1992). Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258, 468–471. doi: 10.1126/science.1411543

Zhao, S., Li, Y., Gao, S., Wang, X., Sun, L., Cheng, D., et al. (2015). Autocrine human urotensin ii enhances macrophage-derived foam cell formation in transgenic rabbits. Biomed Res. Int. 2015:843959. doi: 10.1155/2015/843959

Zhou, L., Xiao, Q., Bi, J., Wang, Z., and Li, Y. (2018). RabGTD: a comprehensive database of rabbit genome and transcriptome. Database. 2018:bay075. doi: 10.1093/database/bay075

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Fan, Wang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.